NPT 200 11

Drug Profile

NPT 200 11

Alternative Names: NPT200-11; UCB-1332

Latest Information Update: 20 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neuropore Therapies
  • Developer Neuropore Therapies; UCB
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action Alpha-synuclein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple system atrophy; Parkinson's disease

Most Recent Events

  • 20 Sep 2016 Phase-I clinical trials in Multiple system atrophy in USA (PO) before September 2016 (Neuropore pipeline, September 2016)
  • 01 Feb 2016 Neuropore Therapies completes a phase I trial in Parkinson's disease (In volunteers) in USA (PO) (NCT02606682)
  • 12 Aug 2015 Phase-I clinical trials in Parkinson's disease (In volunteers) in USA (PO) (NCT02606682)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top